Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer OR breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer OR breast cancer. Displaying page 8 of 41.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2006-001657-94 Sponsor Protocol Number: SPCG 13 Start Date*: 2006-11-16
    Sponsor Name: [...]
    1.
    2. Scandinavian Prostate Cancer Group/ P.O. Hedlund
    Full Title: Randomized adjuvant phase III trial of six cycles of docetaxel+hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiothe...
    Medical condition: Intermediate or high-risk prostate cancer treated with radical radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) IE (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001576-13 Sponsor Protocol Number: FJ-228-0002 Start Date*: 2005-05-17
    Sponsor Name:Gloucester Pharmaceuticals Inc.
    Full Title: An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA.
    Medical condition: Metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    5.0 10036920 CTEP
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003007-38 Sponsor Protocol Number: 56021927PCR3003 Start Date*: 2016-01-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
    Medical condition: High- or very-high risk, localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BE (Trial now transitioned) NL (Completed) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004639-35 Sponsor Protocol Number: 2017/2601 Start Date*: 2018-10-26
    Sponsor Name:Gustave Roussy
    Full Title: A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer
    Medical condition: castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004818-34 Sponsor Protocol Number: CTRIAL-IE-19-32 Start Date*: 2021-04-23
    Sponsor Name:Cancer Trials Ireland
    Full Title: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamid...
    Medical condition: Clinically localised prostate cancer defined as very high risk, or with very high risk features.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002058-41 Sponsor Protocol Number: DISFUNZIONE ERETTILE POST-RT Start Date*: 2007-07-12
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: EFFICACY EVALUATION OF TADALAFIL 20 MG ON DEMAND VS TADALAFIL 5 MG DAILY AS TREATMENT MODALITY FOR ERECTILE DYSFUNCTION FOLLOWING RADICAL RADIOTHERAPY IN PROSTATIC CANCER
    Medical condition: Erectile dysfunction following radiotherapy for prostatic cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10060862 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005595-33 Sponsor Protocol Number: FE200486 CS21 Start Date*: Information not available in EudraCT
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to ...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10060862 pr t
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005201-27 Sponsor Protocol Number: D361EC00001 Start Date*: 2022-06-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Cas...
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing) GR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004103-20 Sponsor Protocol Number: INO-VT-464-CL-001 Start Date*: 2011-10-13
    Sponsor Name:Innocrin Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects with Castration-Resistant Prostate Cancer
    Medical condition: Castration-resistant prostate cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000080-42 Sponsor Protocol Number: Keto1 Start Date*: 2008-03-15
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A Phase II study of Chetoconazolo in patients with Metastatic Hormone-Refractory Prostate Cancer. Pilot study
    Medical condition: Patients with advanced or metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029096 Neoplasm prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003720-32 Sponsor Protocol Number: SPECTRE2015 Start Date*: 2016-06-01
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004295-37 Sponsor Protocol Number: 1-2003 Start Date*: 2005-08-26
    Sponsor Name:Finnish Uro-Oncological Group
    Full Title: A phase III trial comparing docetaxel every third week to biweekly docetaxel monotherapy in metastatic hormone refractory prostate cancer patients.
    Medical condition: Patients with metastatic hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004332-11 Sponsor Protocol Number: P.64Cu.002.02 Start Date*: 2018-03-28
    Sponsor Name:A.C.O.M. -ADVANCED CENTER ONCOLOGY MACERATA -S.R.L.
    Full Title: Use of 64CuCl2 PET/CT Imaging in the selection of patients with prostate cancer in biochemical relapse after prostatectomy, to be successfully treated with salvage radiotherapy on the prostatic bed
    Medical condition: cancer on the prostatic bed
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000799-14 Sponsor Protocol Number: 0080CA002 Start Date*: 2015-01-16
    Sponsor Name:Novalon S. A.
    Full Title: Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with pros...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000842-79 Sponsor Protocol Number: IJB-PROS-PROSPERO-2016 Start Date*: 2016-09-08
    Sponsor Name:Institut Jules Bordet
    Full Title: Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management The ProsPERo Trial
    Medical condition: Males 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on pall...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    19.0 10022891 - Investigations 10068979 Imaging procedure PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004321-86 Sponsor Protocol Number: RN5609C00 Start Date*: 2019-07-24
    Sponsor Name:BioNTech SE
    Full Title: First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 (BNT112) monotherapy and in combination with cemiplimab in patients with pr...
    Medical condition: Male adults with prostate cancer, both mCRPC (Arms 1A & 1B) and LPC (ARms 2&3) patients, will be treated with W_pro1 alone or in combination with cemiplimab. LPC patients will also receive neo-adju...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007113 Cancer of prostate LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015122-11 Sponsor Protocol Number: GBG54 Start Date*: 2012-08-27
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in m...
    Medical condition: Breast Cancer in Male Patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004627-12 Sponsor Protocol Number: CABASEM-SOGUG Start Date*: 2011-12-22
    Sponsor Name:SOGUG - Spanish Oncology Genitourinary Group
    Full Title: Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in "Unfit" Hormone-Refractory Patients Previously Treated with Docetaxel.
    Medical condition: Advanced Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005611-46 Sponsor Protocol Number: TAVT45C02 Start Date*: 2021-06-21
    Sponsor Name:Tavanta Therapeutics, Inc.
    Full Title: Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) Granules for Oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone aceta...
    Medical condition: Metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) SE (Completed) HU (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005042-42 Sponsor Protocol Number: CURF18PSM0001 Start Date*: 2021-06-27
    Sponsor Name:CURIUM Austria GmbH
    Full Title: Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA ...
    Medical condition: Prostate cancer suspected clinically and on the basis of elevated serum Prostate Specific Antigen (PSA) levels and PSA density and with result of multiparametric Magnetic Resonance Imaging (mpMRI) ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10022891 - Investigations 10053838 Free prostate-specific antigen increased PT
    20.1 10022891 - Investigations 10050321 Prostate examination PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029096 Neoplasm prostate PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004385 Benign neoplasm of prostate PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 07:31:11 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA